Last reviewed · How we verify

Italfarmaco — Portfolio Competitive Intelligence Brief

Italfarmaco pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Phlebotonic Phlebotonic marketed Other
Female Contraceptive Female Contraceptive marketed Hormonal contraceptive Progesterone receptor, estrogen receptor Reproductive Health

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. FHI 360 · 1 shared drug class
  2. Kayseri Education and Research Hospital · 1 shared drug class
  3. Penn State University · 1 shared drug class
  4. TherapeuticsMD · 1 shared drug class
  5. University of Alabama at Birmingham · 1 shared drug class
  6. University of Athens · 1 shared drug class
  7. University of Pittsburgh · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Italfarmaco:

Cite this brief

Drug Landscape (2026). Italfarmaco — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/italfarmaco. Accessed 2026-06-09.

Related